Keynote-224. Patients receiving pembrolizumab monotherapy for previously untreated advanced hepatocellular. Pembrolizumab active and well tolerated in pretreated advanced hepatocellular carcinoma


Keynote-224

As you probably already know, dr. Pembrolizumab active and well tolerated in pretreated advanced hepatocellular carcinoma

Keynote-224 Images References :